Standard BioTools Inc. reported fourth‑quarter 2025 revenue of $23.8 million, a 4% decline from the same period last year, and earnings per share of $0.05. The earnings beat analyst consensus of a loss ranging from $-0.07 to $-0.05 per share by $0.10 to $0.15, driven by disciplined cost control and a favorable product mix that offset the 17% year‑over‑year drop in consumables revenue.
The company’s full‑year 2025 results show total revenue of $85.3 million, down 6% from the prior year, and a net loss of $58.8 million, translating to a loss per share of $0.20. The decline reflects weaker demand for consumables and services amid funding constraints, while instrument revenue grew 10% year‑over‑year, partially offsetting the overall revenue contraction.
Gross‑margin performance improved, with GAAP gross margin rising to 47.8% and non‑GAAP margin to 50.3% versus the previous year. The margin expansion is attributable to a higher mix of high‑margin instruments and improved operational leverage, despite the overall revenue decline.
Management highlighted that it has fully operationalized over $40 million in previously announced cost‑saving initiatives, a move that has lowered run‑rate operating expenses and reinforced progress toward 2026 profitability targets. CEO Michael Egholm noted, "We delivered a strong finish to the year with better‑than‑expected performance, driven by disciplined execution across the business." He added, "Our team continued to deliver tangible efficiency gains, fully operationalizing over $40 million in previously announced cost savings and exiting the year with meaningfully lower run‑rate operating expenses, reinforcing progress toward achieving our 2026 profitability targets."
The company reiterated its 2026 revenue outlook of $80 million to $85 million, unchanged from prior guidance. The guidance reflects management’s cautious view of near‑term demand, tempered by the revenue decline seen in 2025, while the strong cash position—bolstered by the January 2026 sale of SomaLogic to Illumina—provides financial flexibility for future growth initiatives.
Overall, Standard BioTools’ Q4 earnings beat and margin improvement signal effective cost discipline, but the year‑over‑year revenue decline and full‑year loss underscore ongoing market headwinds in consumables and services. The company’s focus on operational efficiency and a robust balance sheet positions it to navigate the current environment while pursuing profitability in 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.